X4 Pharmaceuticals, Inc financial data

Symbol
XFOR on Nasdaq, XFOWW on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
61 North Beacon Street, 4 Th Floor, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Arsanis, Inc. (to 3/13/2019)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 505 % -13.5%
Debt-to-equity 214 % +52.8%
Return On Equity -32.5 % +80.9%
Return On Assets -10.3 % +85.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 171M shares +1.95%
Common Stock, Shares, Outstanding 169M shares +2.31%
Entity Public Float 318M USD +974%
Common Stock, Value, Issued 168K USD +1.82%
Weighted Average Number of Shares Outstanding, Basic 201M shares +1.97%
Weighted Average Number of Shares Outstanding, Diluted 201M shares +1.97%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 560K USD
Revenue from Contract with Customer, Excluding Assessed Tax 700K USD
Cost of Revenue 227K USD
Research and Development Expense 75.2M USD -0.72%
General and Administrative Expense 56.3M USD +75.2%
Operating Income (Loss) -25.9M USD +76%
Nonoperating Income (Expense) 9.21M USD -109%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.7M USD +85%
Income Tax Expense (Benefit) 85K USD +44.1%
Net Income (Loss) Attributable to Parent -16.8M USD +84.9%
Earnings Per Share, Basic -0.06 USD/shares +86.4%
Earnings Per Share, Diluted -0.06 USD/shares +86.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 97.4M USD -26%
Cash, Cash Equivalents, and Short-term Investments 135M USD -4.73%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 143M USD -3.31%
Property, Plant and Equipment, Net 820K USD +6.22%
Operating Lease, Right-of-Use Asset 4.47M USD -26.1%
Goodwill 17.4M USD 0%
Other Assets, Noncurrent 2.36M USD +90%
Assets 178M USD +2.81%
Accounts Payable, Current 8.58M USD +5.47%
Employee-related Liabilities, Current 9.21M USD +51.8%
Accrued Liabilities, Current 19.5M USD +20.2%
Liabilities, Current 29.3M USD +15%
Operating Lease, Liability, Noncurrent 1.76M USD -38.3%
Other Liabilities, Noncurrent 1.22M USD +12.5%
Liabilities 119M USD +12.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -114K USD +4.2%
Retained Earnings (Accumulated Deficit) -476M USD -3.65%
Stockholders' Equity Attributable to Parent 59.6M USD -11.8%
Liabilities and Equity 178M USD +2.81%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -120M USD -33.4%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities -5.32M USD -59033%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 169M shares +2.31%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -39M USD -36.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 98.2M USD -25.9%
Deferred Tax Assets, Valuation Allowance 164M USD +23.2%
Deferred Tax Assets, Gross 165M USD +22.7%
Operating Lease, Liability 2.98M USD -24.8%
Lessee, Operating Lease, Liability, to be Paid 3.45M USD -28.5%
Property, Plant and Equipment, Gross 2.64M USD +11.9%
Operating Lease, Liability, Current 1.22M USD +9.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.34M USD -3.86%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.41M USD +3.21%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 469K USD -45.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 292K USD -78%
Deferred Tax Assets, Operating Loss Carryforwards 123M USD +14.6%
Unrecognized Tax Benefits 200K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 49K USD -82.2%
Operating Lease, Payments 1.38M USD +0.36%
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 0 USD
Amortization of Intangible Assets 200K USD
Depreciation, Depletion and Amortization 62K USD -51.2%
Deferred Tax Assets, Net of Valuation Allowance 1.14M USD -24.3%
Share-based Payment Arrangement, Expense 8.53M USD +17.5%
Interest Expense 8.35M USD +65.8%